首页 > 最新文献

Revista Chilena De Infectologia最新文献

英文 中文
Los inicios de la fagoterapia en Chile: los doctores Mercedes Perez Matus y Hugo Vaccaro Kosovich 智利吞噬疗法的开始:梅赛德斯·佩雷斯·马图斯和雨果·瓦卡罗·科索维奇医生
IF 0.5 4区 医学 Q4 Medicine Pub Date : 2022-12-01 DOI: 10.4067/s0716-10182022000600754
Carlos G. Osorio Abarzúa
{"title":"Los inicios de la fagoterapia en Chile: los doctores Mercedes Perez Matus y Hugo Vaccaro Kosovich","authors":"Carlos G. Osorio Abarzúa","doi":"10.4067/s0716-10182022000600754","DOIUrl":"https://doi.org/10.4067/s0716-10182022000600754","url":null,"abstract":"","PeriodicalId":21190,"journal":{"name":"Revista Chilena De Infectologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49500268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recomendación del Comité Asesor de Vacunas y Estrategias de Inmunización (CAVEI) sobre vacunación contra viruela símica en Chile 疫苗和免疫战略咨询委员会关于智利梅毒疫苗接种的建议
IF 0.5 4区 医学 Q4 Medicine Pub Date : 2022-12-01 DOI: 10.4067/s0716-10182022000600731
Vivian Luchsinger, Jeannette Dabanch, A. King, Jan Wilhelm, A. Saldaña, M. P. Bertoglia, C. García, M. L. Endeiza, Jaime Rodríguez
Monkeypox was declared a public health emergency of international concern by the World Health Organization during 2022. In Chile, over 450 patients have been confirmed until September, mostly young men. This zoonotic poxvirus is transmitted from humans to humans through close contact; it is a self-limiting disease and can be fatal in people with immunodeficiency. Prevention by immunization is important. MVA-BN, one of the three vaccines available, it is a third generation vaccine, based on non-replicating modified vaccinia virus, therefore can be administered to immunocompromised patients and pregnant women and it has been approved for monkeypox in people over 18 years of age. The available information on efficacy and effectiveness is limited. The CAVEI recommends incorporating this vaccine to interrupt the chain of transmission and reduce the risk of severe disease, administered subcutaneously in two doses, 28 days apart, prioritizing post exposure use for close contacts of confirmed cases with risk of severe disease, ideally within 4 days of exposure and it can be used up to 14 days after exposure and in the absence of symptoms. When the vaccine supply allows it, its application is recommended as pre-exposure prevention for people with high-risk sexual practices or with occupational risk. This recommendation could be modified according to epidemiology, vaccines supply and new scientific information.
{"title":"Recomendación del Comité Asesor de Vacunas y Estrategias de Inmunización (CAVEI) sobre vacunación contra viruela símica en Chile","authors":"Vivian Luchsinger, Jeannette Dabanch, A. King, Jan Wilhelm, A. Saldaña, M. P. Bertoglia, C. García, M. L. Endeiza, Jaime Rodríguez","doi":"10.4067/s0716-10182022000600731","DOIUrl":"https://doi.org/10.4067/s0716-10182022000600731","url":null,"abstract":"Monkeypox was declared a public health emergency of international concern by the World Health Organization during 2022. In Chile, over 450 patients have been confirmed until September, mostly young men. This zoonotic poxvirus is transmitted from humans to humans through close contact; it is a self-limiting disease and can be fatal in people with immunodeficiency. Prevention by immunization is important. MVA-BN, one of the three vaccines available, it is a third generation vaccine, based on non-replicating modified vaccinia virus, therefore can be administered to immunocompromised patients and pregnant women and it has been approved for monkeypox in people over 18 years of age. The available information on efficacy and effectiveness is limited. The CAVEI recommends incorporating this vaccine to interrupt the chain of transmission and reduce the risk of severe disease, administered subcutaneously in two doses, 28 days apart, prioritizing post exposure use for close contacts of confirmed cases with risk of severe disease, ideally within 4 days of exposure and it can be used up to 14 days after exposure and in the absence of symptoms. When the vaccine supply allows it, its application is recommended as pre-exposure prevention for people with high-risk sexual practices or with occupational risk. This recommendation could be modified according to epidemiology, vaccines supply and new scientific information.","PeriodicalId":21190,"journal":{"name":"Revista Chilena De Infectologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44018538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experiencia de dos años con el uso de panel de RPC múltiple de meningitis-encefalitis en pacientes pediátricos en un hospital de tercer nivel en Argentina 在阿根廷一家三级医院对儿童患者使用脑膜炎-脑炎多重cpr小组两年的经验
IF 0.5 4区 医学 Q4 Medicine Pub Date : 2022-12-01 DOI: 10.4067/s0716-10182022000600713
X. Juárez, Carmen Burundarena, P. Dondoglio, C. Echave, M. LLanos, R. Pereda, A. Cancellara
{"title":"Experiencia de dos años con el uso de panel de RPC múltiple de meningitis-encefalitis en pacientes pediátricos en un hospital de tercer nivel en Argentina","authors":"X. Juárez, Carmen Burundarena, P. Dondoglio, C. Echave, M. LLanos, R. Pereda, A. Cancellara","doi":"10.4067/s0716-10182022000600713","DOIUrl":"https://doi.org/10.4067/s0716-10182022000600713","url":null,"abstract":"","PeriodicalId":21190,"journal":{"name":"Revista Chilena De Infectologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43162164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tinea faciei por Trichophyton violaceum: primer caso alóctono reportado en Chile 紫毛癣菌引起的面部癣:智利报告的第一例异源性病例
IF 0.5 4区 医学 Q4 Medicine Pub Date : 2022-12-01 DOI: 10.4067/s0716-10182022000600740
Raúl Cabrera, Sofía Guelfand, Macarena Stevenson, Marie-Chantal Caussade, D. Velázquez, E. Álvarez
Trichophyton violaceum is an anthropophilic dermatophyte endemic in Africa, Europe, Central America and China. The increase in human mobility has recently contributed to the appearance in non-endemic areas. The main clinical manifestation is tinea capitis followed by tinea corporis . We present the first case in Chile of tinea caused by T. violaceum. The case was a 21 year-old Chilean woman who presented asymptomatic facial plaques one month after arriving from Tanzania, Africa, with no clinical response to previous medical treatments. An allochthonous dermatophytosis was suspected and with special cultures, a slow-growing colony was identified with a violet-blackish color, waxy and rough surface, and velvety villi; all characteristics of T. violaceum . The diagnosis was confirmed by ribo - somal DNA sequencing amplifying the ITS region. She was treated with oral terbinafine obtaining a complete clinical response.
{"title":"Tinea faciei por Trichophyton violaceum: primer caso alóctono reportado en Chile","authors":"Raúl Cabrera, Sofía Guelfand, Macarena Stevenson, Marie-Chantal Caussade, D. Velázquez, E. Álvarez","doi":"10.4067/s0716-10182022000600740","DOIUrl":"https://doi.org/10.4067/s0716-10182022000600740","url":null,"abstract":"Trichophyton violaceum is an anthropophilic dermatophyte endemic in Africa, Europe, Central America and China. The increase in human mobility has recently contributed to the appearance in non-endemic areas. The main clinical manifestation is tinea capitis followed by tinea corporis . We present the first case in Chile of tinea caused by T. violaceum. The case was a 21 year-old Chilean woman who presented asymptomatic facial plaques one month after arriving from Tanzania, Africa, with no clinical response to previous medical treatments. An allochthonous dermatophytosis was suspected and with special cultures, a slow-growing colony was identified with a violet-blackish color, waxy and rough surface, and velvety villi; all characteristics of T. violaceum . The diagnosis was confirmed by ribo - somal DNA sequencing amplifying the ITS region. She was treated with oral terbinafine obtaining a complete clinical response.","PeriodicalId":21190,"journal":{"name":"Revista Chilena De Infectologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41354287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Creación del primer biorrepositorio nacional de bacterias multirresistentes disponible para el estudio de la resistencia bacteriana en Chile 在智利建立第一个用于研究细菌耐药性的国家多重耐药细菌生物库
IF 0.5 4区 医学 Q4 Medicine Pub Date : 2022-10-01 DOI: 10.4067/s0716-10182022000500623
P. García, Lina M Rivas, A. Peters, P. Henríquez, Loriana Castillo, Vijna Illesca, Andrea Maripani, Juan Moreno, Margareta Mühlhauser, Lorena Porte, María Luisa Rioseco, Pamela Rojas, Francisco Silva, P. Suazo, José M. Munita
{"title":"Creación del primer biorrepositorio nacional de bacterias multirresistentes disponible para el estudio de la resistencia bacteriana en Chile","authors":"P. García, Lina M Rivas, A. Peters, P. Henríquez, Loriana Castillo, Vijna Illesca, Andrea Maripani, Juan Moreno, Margareta Mühlhauser, Lorena Porte, María Luisa Rioseco, Pamela Rojas, Francisco Silva, P. Suazo, José M. Munita","doi":"10.4067/s0716-10182022000500623","DOIUrl":"https://doi.org/10.4067/s0716-10182022000500623","url":null,"abstract":"","PeriodicalId":21190,"journal":{"name":"Revista Chilena De Infectologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41376606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infecciones asociadas a la atención de la Salud en pacientes internados en una Unidad de Terapia Intensiva durante la pandemia por COVID-19 en el año 2020 2020年COVID-19大流行期间重症监护病房住院患者的卫生保健相关感染
IF 0.5 4区 医学 Q4 Medicine Pub Date : 2022-10-01 DOI: 10.4067/s0716-10182022000500525
M. Accoce, Betiana A. Guidetto, Javier Hernán Dorado, Lucía Paravano, Mercedes T. Galarza, Irene Paola Outi, A. M. Abrate
Background: Coronavirus disease 2019 (COVID-19) has spread fast globally comprising a great variety of clinical presentations. It was reported that 15% of patients required admission to intensive care units (ICU). Previous epidemiological studies have reported higher risk of healthcare-associated infections (HCAI) in those patients requiring invasive mechanical ventilation (iMV) due to COVID-19. Aim(s): To analyze the incidence of HCAI in adults under iMV admitted to ICU of Anchorena San Martin Clinic during COVID-19 pandemic. Method(s): Retrospective cohort study, the analysis of normality was carried out using the Shapiro-Wilk test. The multiple regression analysis was performed automatically, based on backward elimination of the variables (backward selection). For the comparison between the COVID-19 and non-COVID-19 groups, the T test or Wilcoxon test was used, as appropriate;and the chi2 or Fisher's exact test. All cumulative incidence function estimates were made with the cmprsk package. Result(s): 252 patients were included, 40 patients developed HCAI (accumulated incidence was 15.9%), counting for 60 total HCAI events. Age (OR 0.96), number of central venous access devices (CVAD) (OR 2.01), COVID-19 (OR 2.96) and prone positioning (OR 2.78) were associated with HCAI. HCAI was associated with more days of iMV and ICU stay. The accumulated incidence of HCAI in non-COVID-19 patients was lower than in COVID-19 patients. iMV days and mortality were higher in COVID-19. 29.6% of COVID-19 patients developed HCAIs vs 7.1% of non-COVID-19 ones. Conclusion(s): We describe the incidence of HCAI. Age, COVID-19, CVAD, prone positioning and ICU stay were associated with higher probability of HCAIs.Copyright © 2022, Sociedad Chilena de Infectologia. All rights reserved.
背景:2019冠状病毒病(COVID-19)在全球迅速传播,临床表现多种多样。据报道,15%的患者需要入住重症监护病房(ICU)。先前的流行病学研究报告称,在因COVID-19而需要有创机械通气(iMV)的患者中,医疗保健相关感染(HCAI)的风险更高。目的:分析2019冠状病毒病(COVID-19)大流行期间安克雷纳圣马丁诊所ICU住院iMV成人HCAI的发生率。方法:回顾性队列研究,采用Shapiro-Wilk检验进行正态性分析。自动进行多元回归分析,基于反向消除变量(反向选择)。对于COVID-19组和非COVID-19组之间的比较,酌情使用T检验或Wilcoxon检验,以及chi2或Fisher确切检验。所有累积关联函数估计都是用cprsk包进行的。结果:纳入252例患者,发生HCAI 40例(累计发病率15.9%),合计60例HCAI事件。年龄(OR 0.96)、中心静脉通路装置(CVAD)数量(OR 2.01)、COVID-19 (OR 2.96)和俯卧位(OR 2.78)与HCAI相关。HCAI与iMV和ICU住院天数增加有关。HCAI在非COVID-19患者中的累积发病率低于COVID-19患者。COVID-19的病毒感染天数和死亡率更高。29.6%的COVID-19患者发生hcai,非COVID-19患者为7.1%。结论:我们描述了HCAI的发生率。年龄、COVID-19、CVAD、俯卧位和ICU住院时间与hcai发生的可能性相关。智利感染学会版权所有©2022。版权所有。
{"title":"Infecciones asociadas a la atención de la Salud en pacientes internados en una Unidad de Terapia Intensiva durante la pandemia por COVID-19 en el año 2020","authors":"M. Accoce, Betiana A. Guidetto, Javier Hernán Dorado, Lucía Paravano, Mercedes T. Galarza, Irene Paola Outi, A. M. Abrate","doi":"10.4067/s0716-10182022000500525","DOIUrl":"https://doi.org/10.4067/s0716-10182022000500525","url":null,"abstract":"Background: Coronavirus disease 2019 (COVID-19) has spread fast globally comprising a great variety of clinical presentations. It was reported that 15% of patients required admission to intensive care units (ICU). Previous epidemiological studies have reported higher risk of healthcare-associated infections (HCAI) in those patients requiring invasive mechanical ventilation (iMV) due to COVID-19. Aim(s): To analyze the incidence of HCAI in adults under iMV admitted to ICU of Anchorena San Martin Clinic during COVID-19 pandemic. Method(s): Retrospective cohort study, the analysis of normality was carried out using the Shapiro-Wilk test. The multiple regression analysis was performed automatically, based on backward elimination of the variables (backward selection). For the comparison between the COVID-19 and non-COVID-19 groups, the T test or Wilcoxon test was used, as appropriate;and the chi2 or Fisher's exact test. All cumulative incidence function estimates were made with the cmprsk package. Result(s): 252 patients were included, 40 patients developed HCAI (accumulated incidence was 15.9%), counting for 60 total HCAI events. Age (OR 0.96), number of central venous access devices (CVAD) (OR 2.01), COVID-19 (OR 2.96) and prone positioning (OR 2.78) were associated with HCAI. HCAI was associated with more days of iMV and ICU stay. The accumulated incidence of HCAI in non-COVID-19 patients was lower than in COVID-19 patients. iMV days and mortality were higher in COVID-19. 29.6% of COVID-19 patients developed HCAIs vs 7.1% of non-COVID-19 ones. Conclusion(s): We describe the incidence of HCAI. Age, COVID-19, CVAD, prone positioning and ICU stay were associated with higher probability of HCAIs.Copyright © 2022, Sociedad Chilena de Infectologia. All rights reserved.","PeriodicalId":21190,"journal":{"name":"Revista Chilena De Infectologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48425087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Caracterización fenotípica y molecular de cepas de Klebsiella pneumoniae productores de carbapenemasas tipo OXA-48 circulantes en Chile 智利循环中产生Oxa-48型碳青霉烯酶的肺炎克雷伯菌菌株的表型和分子特征
IF 0.5 4区 医学 Q4 Medicine Pub Date : 2022-10-01 DOI: 10.4067/s0716-10182022000500551
Ingrid Araya, Freddy Roach-Poblete, T. Tapia, Paula I. Rodas, Aura Villamil, Rocío Aguero, R. Iglesias, D. Garate, Oscar Duery, R. Flores, Daniel Ibáñez, J. Fernández, Pamela Araya, Mauro Orsini, J. C. Hormazábal
{"title":"Caracterización fenotípica y molecular de cepas de Klebsiella pneumoniae productores de carbapenemasas tipo OXA-48 circulantes en Chile","authors":"Ingrid Araya, Freddy Roach-Poblete, T. Tapia, Paula I. Rodas, Aura Villamil, Rocío Aguero, R. Iglesias, D. Garate, Oscar Duery, R. Flores, Daniel Ibáñez, J. Fernández, Pamela Araya, Mauro Orsini, J. C. Hormazábal","doi":"10.4067/s0716-10182022000500551","DOIUrl":"https://doi.org/10.4067/s0716-10182022000500551","url":null,"abstract":"","PeriodicalId":21190,"journal":{"name":"Revista Chilena De Infectologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48686531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Bronquiolitis obliterante y SARS-CoV-2: el inicio de una asociación 闭塞性细支气管炎与SARS-CoV-2:关联的开始
IF 0.5 4区 医学 Q4 Medicine Pub Date : 2022-10-01 DOI: 10.4067/s0716-10182022000500649
Juliana Quintero Salazar, A. Ceballos, Leonardo Múnera Montes, Andrea Parra Buitrago, Jorge García Ciro
{"title":"Bronquiolitis obliterante y SARS-CoV-2: el inicio de una asociación","authors":"Juliana Quintero Salazar, A. Ceballos, Leonardo Múnera Montes, Andrea Parra Buitrago, Jorge García Ciro","doi":"10.4067/s0716-10182022000500649","DOIUrl":"https://doi.org/10.4067/s0716-10182022000500649","url":null,"abstract":"","PeriodicalId":21190,"journal":{"name":"Revista Chilena De Infectologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45246936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Declaración SLIPE: Aumento de la cobertura antipoliomielítica con vacunas más seguras: una urgencia inaplazable en Latinoamérica SLIPE声明:用更安全的疫苗增加脊髓灰质炎覆盖率:拉丁美洲不可推迟的紧急情况
IF 0.5 4区 医学 Q4 Medicine Pub Date : 2022-10-01 DOI: 10.4067/s0716-10182022000500604
L. H. Falleiros-Arlant, M. L. Ávila-Agüero, J. Castillo, A. Gentile, Jaime R. Torres, D. Roberto
{"title":"Declaración SLIPE: Aumento de la cobertura antipoliomielítica con vacunas más seguras: una urgencia inaplazable en Latinoamérica","authors":"L. H. Falleiros-Arlant, M. L. Ávila-Agüero, J. Castillo, A. Gentile, Jaime R. Torres, D. Roberto","doi":"10.4067/s0716-10182022000500604","DOIUrl":"https://doi.org/10.4067/s0716-10182022000500604","url":null,"abstract":"","PeriodicalId":21190,"journal":{"name":"Revista Chilena De Infectologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44932383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Producción de vacunas en el antiguo Instituto Bacteriológico de Chile 在智利前细菌学研究所生产疫苗
IF 0.5 4区 医学 Q4 Medicine Pub Date : 2022-10-01 DOI: 10.4067/s0716-10182022000500659
Walter Ledermann Dehnhardt
{"title":"Producción de vacunas en el antiguo Instituto Bacteriológico de Chile","authors":"Walter Ledermann Dehnhardt","doi":"10.4067/s0716-10182022000500659","DOIUrl":"https://doi.org/10.4067/s0716-10182022000500659","url":null,"abstract":"","PeriodicalId":21190,"journal":{"name":"Revista Chilena De Infectologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44449211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista Chilena De Infectologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1